Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

BACKGROUND: Efficacy and safety of long-acting cabotegravir (CAB) + rilpivirine (RPV) every 8 weeks (Q8W) versus daily oral standard of care (SoC) maintenance in treatment-experienced individuals with virologically suppressed human immunodeficiency virus type 1 (HIV-1) has not been directly compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Chounta, Vasiliki, Snedecor, Sonya J., Wu, Sterling, Van de Velde, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066757/
https://www.ncbi.nlm.nih.gov/pubmed/35508986
http://dx.doi.org/10.1186/s12879-022-07243-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066757/
https://www.ncbi.nlm.nih.gov/pubmed/35508986
http://dx.doi.org/10.1186/s12879-022-07243-3

Ejemplares similares